Jackie Whitesell, MD
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,045 of the $2,391 with a category attached, or 85.5%. It is spread thinly across 31 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $931 and has fallen 63.5% since, to $340 in 2025.
Across 85 payments — averaging $28.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$409
- Argenx US, Inc.$350
- Novartis$217
- AbbVie$188
- Acadia Pharmaceuticals Inc$151
- EMD Serono, Inc.$139
- plus $938 from 25 others
What the payments were for
- Speaking & faculty fees$532%
- Food & beverage$2,04586%
- Education$29312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 8 | $409 |
| Argenx US, Inc. | 4 | $350 |
| Novartis | 8 | $217 |
| AbbVie(2 entities) | 10 | $188 |
| Acadia Pharmaceuticals Inc | 7 | $151 |
| EMD Serono, Inc. | 7 | $139 |
| TG Therapeutics, Inc. | 2 | $129 |
| Tanabe Pharma America, Inc. | 6 | $112 |
| Stimwave Technologies Incorporated | 1 | $73 |
| SK Life Science, Inc. | 1 | $54 |
| Acorda Therapeutics, Inc | 3 | $53 |
| Sarepta Therapeutics, Inc. | 2 | $52 |
| Livanova USA, Inc. | 2 | $50 |
| Supernus Pharmaceuticals, Inc. | 3 | $45 |
| Lilly USA, LLC | 3 | $45 |
| EDW Pharma, Inc. | 1 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Merz Pharmaceuticals, LLC | 1 | $28 |
| Cycle Pharmaceuticals Inc | 1 | $26 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
| Sanofi | 1 | $22 |
| Pfizer | 1 | $22 |
| Eisai Inc. | 1 | $19 |
| Bristol Myers Squibb | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| CSL Behring | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$125
- BRIUMVI$109
- MAYZENT$108
- VYVGART HYTRULO$105
How this compares
$2,391 in reported general payments places this provider in the 65th percentile of 59 neurology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EvrysdiRisdiplam | 15 | $417,172 |
| Kesimpta PenOfatumumab | 27 | $250,809 |
| Radicava OrsEdaravone | 14 | $179,500 |
| Dimethyl Fumarate | 57 | $118,274 |
| Teriflunomide | 35 | $117,080 |
| QuliptaAtogepant | 80 | $85,796 |
| Nurtec OdtRimegepant Sulfate | 35 | $55,530 |
| Emgality PenGalcanezumab-Gnlm | 41 | $36,426 |
| Lamotrigine ErLamotrigine | 31 | $32,514 |
| Ajovy SyringeFremanezumab-Vfrm | 28 | $26,976 |
| GlatopaGlatiramer Acetate | 19 | $25,785 |
| Riluzole | 57 | $23,454 |
| Emgality SyringeGalcanezumab-Gnlm | 30 | $20,707 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 19 | $18,502 |
| AptiomEslicarbazepine Acetate | 12 | $17,722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $188 | $99,36693 claims |
| PfizerNurtec Odt | $22 | $55,53035 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $26 | $17,72212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 59 neurology providers in Idaho.
Other neurology in Boise
- Sergei KashirnyBoise$20K
- Anant WadhwaBoise$6K
- Brittany LovascioBoise$2K
- Benjamin StewartBoise$2K
- Matthew TechyBoise$2K
- Kelly BlockBoise$2K
- Thomas StrobelBoise$1K
- Lukas ClarkBoise$1K
- James WhitesideBoise$1K
- Daniel SimmonsBoise$729
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.